mr. coukell. >> i think it is important to have some label there. in a practical sense what we do in the hospital to prevent overuse of certain drugs is we already have stewardship in place. in our county hospital, whatever reason have to go through an infectious disease approval. that's already in place. another thing we sometimes do is we don't report on the chart of the report that goes to the patient's chart, the susceptibility certain antibiotics. if you're in infectious diseases or are smart enough to know what's going on you know to call the laboratory and ask for that so the doctors that are caring for this multi-drug-resistant infections know to do that. usually is done because there's certain combinations that even though the antibiotic is susceptible you wouldn't use it alone. the third way with electronic records that might be possible that i was speaking about last night was that when this drug is written for there's an automatic pop-up. with all sorts of automatic pop-ups now an automatic pop-up could say this has been approved in a li

mr. coukell. you want to respond? >> we've worked very closely on this bill and we think this is the one place we really would like to see improvement. as i said in my testimony, it is important to convey to the provider for special status and nature of the struts unless recognized the labeling is not affect it when someone looks at the fine print, but the start of the process of how information about the drug is promulgated in the community through the medical record, marketing materials and so on. we have called for a logo to distinguish drugs. as long as it is communicated clearly that the strokes are different and that is part of what congress is doing by creating this designation. >> all right. thanks a lot. >> one rethink some of the other thing in the bill that we think it's important how to monitor the drug sobieski tackett know their indication is working as intended. >> all right. they experience the next chair thanks the gentleman. the shuttle and from illinois, mr. shimkus. >> thank you, mr. chairman. this

mr. coukell. >> i think it is important to have some label there. in a practical sense what we do in the hospital to prevent overuse of certain drugs is we already have stewardship in place. in our county hospital, whatever reason have to go through an infectious disease approval. that's already in place. another thing we sometimes do is we don't report on the chart of the report that goes to the patient's chart, the susceptibility certain antibiotics. if you're in infectious diseases or are smart enough to know what's going on you know to call the laboratory and ask for that so the doctors that are caring for this multi-drug-resistant infections know to do that. usually is done because there's certain combinations that even though the antibiotic is susceptible you wouldn't use it alone. the third way with electronic records that might be possible that i was speaking about last night was that when this drug is written for there's an automatic pop-up. with all sorts of automatic pop-ups now an automatic pop-up could say this has been approved in a li